Day: September 5, 2025

TORONTO, Sept. 04, 2025 (GLOBE NEWSWIRE) — Future Mineral Resources Inc. (formerly Sulliden Mining Capital Inc.) (“Future Mineral” or the “Company”) (TSX: SMC) is pleased to announce that (i) it has changed its name from Sulliden Mining Capital Inc. to Future Mineral Resources Inc. and (ii) the board of directors of the Company has authorized the implementation of a consolidation (the “Consolidation”) of the Company’s common shares (the “Shares”) on the basis of one post-Consolidation Share for every 10 pre-Consolidation Shares, each effective September 5, 2025. Future Mineral currently has 166,875,979 Shares issued and outstanding. Following completion of the Consolidation, the Company will have approximately 16,687,597 Shares issued and outstanding. No fractional Shares will be issued pursuant to the Consolidation; fractional...

Not for release to U.S. wire services or for distribution in the United States VANCOUVER, British Columbia, Sept. 04, 2025 (GLOBE NEWSWIRE) — Marimaca Copper Corp. (TSX: MARI) (ASX: MC2) (“Marimaca” or the “Company”) announces that further to the previously announced best-efforts brokered placement in Australia and select other jurisdictions outside of Australia, except for Canada, the Company will issue an aggregate of 8,247,423 Chess Depositary Interests (“CDI”) at a price of A$9.70(1) per CDI for gross proceeds of approximately A$80,000,000 or approximately C$72,080,000 (the “Placement”). The net proceeds from the Placement will be used for detailed design and engineering and project related workstreams at the Marimaca Oxide Deposit (the “MOD”), exploration at the Pampa Medina Project and Marimaca sulphide target, and for general...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 05, 2025 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the 2025 World Conference on Lung Cancer (“WCLC”) taking place on September 6-9, 2025 in Barcelona, Spain, and the Chinese Society of Clinical Oncology (“CSCO”) Annual Meeting 2025, taking place on September 10-14, 2025 in Jinan, China. Updated analysis from savolitinib’s SACHI, SAVANNAH and a Phase IIIb confirmatory study in non-small cell lung cancer (“NSCLC”) patients will be presented at WCLC 2025. Savolitinib is an oral, potent and highly selective MET tyrosine kinase inhibitor (“TKI”) being jointly developed by AstraZeneca and HUTCHMED and commercialized by AstraZeneca....

SMITHFIELD, Va., Sept. 04, 2025 (GLOBE NEWSWIRE) — Smithfield Foods, Inc. (Nasdaq: SFD) (the “Company”), an American food company and an industry leader in value-added packaged meats and fresh pork, today announced the pricing of a secondary public offering of 19,531,698 shares of common stock of the Company sold by SFDS UK Holdings Limited, the principal shareholder of the Company, at a price to the public of $23.25 per share. In addition, the selling shareholder has granted the underwriters a 30-day option to purchase up to 2,929,754 additional shares of the Company’s common stock at the public offering price, less underwriting discounts and commissions. The Company is not selling any shares of common stock in the offering and will not receive any proceeds from the sale of the shares by the selling shareholder, including from...